In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Bonus Apr 08, 1994 May 03, 1994 Mar 24, 1994 Bonus Ratio: 2 share(s) for every 1 shares held Bonus Dec 04, 1992 Dec 22, 1992 Sep 30, 1992 Bonus Ratio: 1 share(s) for every 1 shares held Dr. Reddy's ...